The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis

Abstract

Our data suggest that p53 may be used as a prognostic marker in osteosarcoma due to its significant association with survival.

Heat shock protein expression in canine osteosarcoma

“…Our results concerning Hsp90 correspond to its role as a specialized molecular chaperone, responsible for folding numerous oncogenic proteins and thus leading to an 'addiction' to this Hsp by cancer cells (Trepel et al 2010). Information regarding its expression in human OSA tissues is limited (Uozaki et al 2000;Ozger et al 2009), although several studies have highlighted the possible effectiveness of Hsp90-binding agents, particularly 17-allylamino-17-demethoxygeldanamicin (17-AAG), in the targeted therapy of this kind of tumour, especially in the context of childhood sarcomas (Bagatell et al 2005;Gazitt et al 2009). In addition, McCleese et al (2009) have recently demonstrated the selective cytotoxicity of the novel Hsp90 inhibitor STA-1474 for human and canine OSA cell lines.…”

“…Similar studies have been carried out in human OSA (Trieb et al 1998;Uozaki et al 2000;Ozger et al 2009;Moon et al 2010). However, results published in literature are conflicting: Hsp27, Hsp60 and Hsp70 overexpression have been related to poor prognosis by some studies (Uozaki et al 2000) whilst others have failed to demonstrate any significant influence on the survival rate in human OSA (Ozger et al 2009;Moon et al 2010). The results of the present study do not show a significant relationship between the expression scores of the different HSPs evaluated and OS, although absence of Hsp72 immunosignal appeared to be related to a longer postsurgical OS (P=0.006), with also a tendency toward a prolonged OS for its lower expression levels (P=0.058), and a significant association was found between high Hsp72 immunodetection and high-grade OSA.…”

“…Similar studies have been carried out in human OSA (Trieb et al 1998;Uozaki et al 2000;Ozger et al 2009;Moon et al 2010). However, results published in literature are conflicting: Hsp27, Hsp60 and Hsp70 overexpression have been related to poor prognosis by some studies (Uozaki et al 2000) whilst others have failed to demonstrate any significant influence on the survival rate in human OSA (Ozger et al 2009;Moon et al 2010).…”

“…The results of this study suggest the involvement of Hsp90 in the pathogenesis of canine OSA although no association seems to exist b-c Hsp72 expression scores did not show a significant relation to OS (P=0. 058-P=0.112) between its expression and tumour prognosis, similarly to humans (Uozaki et al 2000;Ozger et al 2009). Lastly, the widespread expression of this protein observed both in primary tumours and in neoplastic emboli strongly highlights the possibility of using a canine model for further testing of Hsp90-targeted cancer therapy.…”

“…Since abnormal HSP levels have been observed in a wide range of human tumours, a number of studies have been carried out in order to determine whether these proteins could be used as diagnostic, prognostic and/or predictive markers or represent new molecular targets for cancer therapy (Ciocca and Calderwood 2005;Karapanagiotou et al 2009). In particular, several studies have been performed to investigate the expression and prognostic significance of HSPs in human osteosarcoma (OSA; Trieb et al 1998;Uozaki et al 2000;Ozger et al 2009;Moon et al 2010). In addition, during the last decade, researches have been focused on the potential usefulness of Hsp90 inhibitors as novel treatment approaches of cancer (Porter et al 2010), including OSA (Gazitt et al 2009), particularly in the context of childhood sarcomas (Bagatell et al 2005;.…”